Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 3/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15542269 | 0.86 | NTRK1 (0.40) | NTRK1NTRK3MAPK1EPHX2TRPA1 | |
| SCHEMBL23830502 | 0.77 | PDPK1 (0.36) | PDPK1JAK2IDO1TRPA1 | |
| SCHEMBL30536586 | 0.77 | PDPK1 (0.36) | PDPK1JAK2IDO1TRPA1 | |
| SCHEMBL11970930 | 0.74 | ADORA2A (0.47) | PDPK1JAK2MAPK1IDO1 | |
| SCHEMBL30599435 | 0.74 | PDPK1 (0.34) | PDPK1JAK2IDO1 | |
| SCHEMBL25394513 | 0.74 | TRPA1 (0.35) | PDPK1JAK2IDO1TRPA1 | |
| SCHEMBL17678215 | 0.74 | PDPK1 (0.34) | PDPK1JAK2IDO1 | |
| SCHEMBL16252839 | 0.72 | MAP2K4 (0.51) | NTRK1NTRK3MAPK1 | |
| SCHEMBL15541661 | 0.72 | NTRK1 (0.56) | NTRK1NTRK3 | |
| SCHEMBL11977413 | 0.72 | PDPK1 (0.58) | NTRK3CSNK2A1PDPK1JAK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804911-A | Acrylamide compound | NRG治疗有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | NTRK1 4106/4885NTRK3 3885/4885CSNK2A1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.